Advertisement

Document › Details
Polyplus-transfection S.A.. (11/29/18). "Press Release: Polyplus-transfection Launches a Powerful Nanotechnology for DNA Transfection Composed of jetOptimus Reagent".
![]() |
Organisation | Polyplus-transfection S.A. |
Group | Polyplus-transfection (Group) | |
![]() |
Product | jetOptimus® reagent for nanoparticle DNA transfection |
Product 2 | transfection reagents | |
Polyplus-transfection® SA, a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics, today announces the launch of jetOPTIMUS®, a new reagent for powerful nanoparticle DNA transfection.
“As cell and gene therapies become more advanced and complex, this increases the need to address DNA transfection of very challenging cells. To increase efficiency in hard-to-transfect cells, scientists have to use ever-more advanced reagents,” said Patrick Erbacher, CSO, Polyplus-transfection. “We recognized the need to combine the efficiency, safety and morphology requirements of mammalian cell transfection. To date, the market has not supplied what is expected today to fulfil all needs. Polyplus-transfection believes jetOPTIMUS will equip academics in the most advanced cell and gene therapy based research with the best solution.”
The reagent has been designed to be primarily used for research purposes across academic research in mammalian cells, especially hard-to-transfect cells. The reagent will result in the most efficient mammalian cell transfection product on the market, maximizing gene expression. This ensures improved cell viability and morphology after transfection for more relevant data. The requirement of a minimal reagent volume and DNA quantity will considerably increase costefficiency. The cost per reaction will be decreased by up to seven times when compared to other market leading products.
The reagent is the latest product in the Polyplus-transfection portfolio of reagents for the transfection of genes, oligonucleotides and siRNA. jetOPTIMUS has been designed to be the best-in-class DNA transfection reagent for everyday transfection experiments. It will provide solutions for those working with all types of cells and transfection applications. It solves a range of issues encountered across the market with hard to transfect cells.
About Polyplus-transfection
Polyplus-transfection SA is a biotechnology company specializing in delivery solutions and a market leader for transfection reagents for cell & gene therapy. Polyplus-transfection’s vast portfolio of delivery solutions can be used for all types of applications, from research and process development, all the way to clinical trials. Located close to the University of Strasbourg in Eastern France, Polyplustransfection has been ISO 9001-certified since 2002.
Press Contact
Polyplus-transfection SA
Géraldine Guérin-Peyrou
phone: +33 (0)3 90406186
e-mail: ggp@polyplus-transfection.com
Record changed: 2018-12-04 |
Advertisement

More documents for Polyplus-transfection (Group)
- [1] Polyplus-transfection S.A.. (11/2/20). "Press Release: Polyplus-transfection Names Mario Philips as Chief Executive Officer". Illkirch....
- [2] Polyplus-transfection S.A.. (4/29/20). "Press Release: Growth Investment Is Set to accelerate Polyplus’ Expansion in Partnership with Warburg Pincus and ArchiMed". Illkirch....
- [3] Polyplus-transfection S.A.. (12/13/18). "Press Release: Polyplus-transfection further Expands Transfection Reagent Portfolio for Cell and Gene Therapy GMP production". Strasbourg....
- [4] Polyplus-transfection S.A.. (7/6/18). "Press Release: Polyplus-transfection Launches New Advanced System for Transient Protein Expression in CHO cells". Strasbourg....
- [5] Polyplus-transfection S.A.. (9/19/16). "Press Release: ArchiMed Acquires Biotech Specialist Polyplus-transfection"....
- [6] Lippold, Marcus. (1/30/15). "[LSE] Interview: An Exclusive Interview with Mark Bloomfield, CEO of Polyplus-transfection S.A., on the Policies of Larger Companies with Regard to IP of Smaller Firms (Part 3)"....
- [7] Lippold, Marcus. (1/13/15). "[LSE] Interview: An Exclusive Interview with Mark Bloomfield, CEO of Polyplus-transfection S.A., on the Policies of Larger Companies with Regard to IP of Smaller Firms"....
- [8] Lippold, Marcus. (1/13/15). "[LSE] Interview: An Exclusive Interview with Mark Bloomfield, CEO of Polyplus-transfection S.A., on the Policies of Larger Companies with Regard to IP of Smaller Firms (Part 2)"....
- [9] Polyplus-transfection S.A.. (10/28/14). "Press Release: Polyplus-transfection and Blue Sky BioServices Sign a Research and Commercial License Agreement for Use of PEI-based Transfection Technologies". Strasbourg....
- [10] Polyplus-transfection S.A.. (2/17/14). "Press Release: Polyplus-transfection and the National Institute of Health Sign a Research License Agreement for PEI-based Transfection Technologies". Strasbourg....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top